相关实验视频
Updated: Jan 15, 2026

06:10
Seizure Activity Induced by Electroshock in Drosophila Larvae
Published on: June 6, 2025
770
一项关于不同组合抗发作药物疗法的疗效的比较研究,该研究是在氨酸单一治疗失败后进行的
Raowei Yan1, Hesheng Zhang1, Jia He2
1Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Acta epileptologica
|October 15, 2025
概括
对于没有对甲酸单独治疗反应的患者,添加拉莫特里金 (LTG) 对泛性发作有更高的疗效,而对焦点发作更有效的是牛bazepine (OXC).
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 酸 (VPA) 是一种一线治疗方法.
- 在VPA单一疗法失败后,最佳补充治疗的证据有限.
- 有几种广泛的抗发作药物 (ASM),包括lamotrigine (LTG), levetiracetam (LEV),oxcarbazepine (OXC),topiramate (TPM) 和carbamazepine (CBZ) 在内.
研究的目的:
- 为了比较不同ASM的治疗疗效,作为附加治疗在患者 (PWE) 谁失败了VPA单一治疗.
- 根据扣押类型确定最有效的附加ASM组合.
主要方法:
- 一项涉及2656个PWE的比较研究分为五个附加组:VPA+LTG,VPA+LEV,VPA+TPM,VPA+OXC和VPA+CBZ.
- 根据发作发作分组:普遍发作,焦点发作或未知发作.
- 用差异,奇二次测试和卡普兰-梅尔生存分析来分析有效性.
主要成果:
- 对于一般性,VPA+LTG (89.6%) 的反应率 (≥50%) 是最高的,其次是VPA+OXC (81.0%),VPA+LEV (77.9%),VPA+TPM (77.7%) 和VPA+CBZ (75.9%). LTG的疗效明显高于LEV,TPM和CBZ. LTG的疗效明显高于LEV,TPM和CBZ.
- 对于焦点,VPA+OXC (88.9%) 和VPA+LTG (86.3%) 的反应率最高,其次是VPA+LEV (79.3%),VPA+TPM (75.9%) 和VPA+CBZ (74.8%). OXC明显比LEV,TPM和CBZ更有效.
结论:
- 在VPA单一疗法失败时,拉莫特里金 (LTG) 似乎是治疗一般性的更有效的补充疗法.
- 牛炭bazepine (OXC) 证明了优越的疗效作为一个add-on治疗焦点的患者之前的VPA单一治疗失败.
- 这些发现提供了现实世界的证据,以指导为优化管理的临床决策.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
822
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
822
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
632
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
632
Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Electroconvulsive Therapy
891
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
891
Antiepileptic Drugs: Glutamate Antagonists
893
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
893

